Access & Innovation
In the village of Gegema, Solomon Islands, health worker takes blood samples for rapid diagnostic tests. © Global Fund / John Rae
Timely access to game changing malaria commodities could accelerate progress towards malaria elimination in Asia Pacific. This includes diagnostic tools, treatment to counter drug-resistant malaria and the unresolved burden of P. vivax malaria, as well as new vector control products. However, several barriers stand in the way of their speedy registration and use.
The region needs a better view of the pipeline of innovations and a clearer understanding of how the suite of existing and new commodities can support the region’s malaria response. Unless some of the key access and regulatory bottlenecks are addressed, there will be delays in the registration of game-changing innovations and missed opportunities to detect and treat remaining cases.
“We cut through today’s cluttered public health landscape, working to fast-track new solutions and unblock the bottlenecks which prevent life-saving solutions from reaching those in need.”
APLMA facilitates partnerships to sustain access to new and existing tools to prevent malaria, tests to detect malaria, and treatments to cure malaria. Our work is also focused on ensuring medicine quality and anchoring to Universal Health Coverage.
A health innovation series that gathers Senior Officials from Asia Pacific, National Regulatory Authorities, manufacturers of malaria commodities and global health partners to discuss existing and new tools and strategies to advance both health security and malaria elimination in the region.
Vector Control Platform for Asia Pacific
In recognition of vector diversity, vector behaviour differences and the need overcome some of the policy barriers to effective vector control in support of malaria elimination, the Alliance and Unitaid jointly established the Vector Control Platform for Asia Pacific (VCAP).
Regional Regulatory Partnership for Malaria Elimination (RRPME)
Strengthening national regulatory capacity and regional collaboration on pharmaceutical regulatory practices.